Boehringer Ingelheim is a German pharmaceutical company founded in 1885 in Ingelheim am Rhein. It is headquartered in Ingelheim and operates globally across human pharmaceuticals, animal health, and biopharmaceuticals. The company is privately held and owned by the Boehringer, Liebrecht, and von Baumbach families.
AI-driven drug discovery attracts major investment and partnerships: Galux closes $29M Series B, LG Chem partners with LabGenius on cancer antibodies, Cheiron raises $8M seed, and Peptris secures $7.7M. Galux also teams with AimedBio on BBB-crossing proteins.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Zai Lab's Q1 2026 revenue fell 6% to $99.6 million, missing expectations, while EPS beat at -$0.05. The company highlighted Zoci intracranial response data and expects three pivotal trials by year-end 2026.
Japan's Intellectual Property High Court upheld three Boehringer Ingelheim patents for linagliptin, rejecting challenges by Nipro. It also upheld the revocation of a separate dosage patent, calling the regimen a routine refinement within known ranges.
Galux completed a $29 million Series B financing and entered an MOU with OliX Pharmaceuticals to jointly develop a next-generation AI-based siRNA delivery platform. The funding will support GaluxDesign, R&D expansion and preclinical validation.
Deupirfenidone, a deuterated form of pirfenidone, is set to be tested in a phase 3 trial this year after successful phase 2b results. The FDA and European Commission have granted orphan drug designation to support its late-stage development.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Zealand Pharma reported full-year 2025 revenue of DKK 9.2 billion, bolstered by a significant upfront payment from Roche. The company ended the year with DKK 15.1 billion in cash and set 2026 operating expense guidance between DKK 2.72 billion and DKK 3.3 billion.
The large molecule drug substance CDMO market is expected to grow at approximately 9% CAGR through 2031, driven by rising demand for biologics and biosimilars, streamlined regulatory approval pathways, and increasing FDA and EMA approvals for biologic therapies.
Four biotech companies went public in one week raising nearly $1 billion, signaling a potential thaw in IPO markets after years of quiet activity. Regional life sciences hubs outside Boston and San Francisco are attracting record venture funding, while regulatory uncertainty at FDA continues to concern industry leaders.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774325 |
A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Blood |
NOT_YET_RECRUITING | PHASE1 |
| NCT07768813 |
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07760246 |
A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart |
NOT_YET_RECRUITING | PHASE1 |
| NCT07754474 |
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07754461 |
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar |
RECRUITING | PHASE3 |
| NCT07744152 |
A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07743996 |
Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World Study |
RECRUITING | |
| NCT07727785 |
A Study in Healthy People to Compare Two Tablet Formulations of Pramipexole |
RECRUITING | PHASE1 |
| NCT07708493 |
A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight |
NOT_YET_RECRUITING | PHASE1 |
| NCT07707895 |
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
